Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Joey L, Methot"'
Autor:
Yun Wang, Kelvin Zhang, Peter Georgiev, Steven Wells, Haiyan Xu, Brian M Lacey, Zangwei Xu, Jason Laskey, Robbie Mcleod, Joey L Methot, Mark Bittinger, Alexander Pasternak, Sheila Ranganath
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243145 (2020)
Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-specific Ste20-related serine/threonine kinase, is a negative regulator of signal transduction in immune cells, including T cells, B cells, and dendritic cells (DCs). In mice, HPK1 defici
Externí odkaz:
https://doaj.org/article/122f7b4dd63e4038920f174d5a32c1d4
Autor:
David A. Candito, Vladimir Simov, Anmol Gulati, Solomon Kattar, Ryan W. Chau, Blair T. Lapointe, Joey L. Methot, Duane E. DeMong, Thomas H. Graham, Ravi Kurukulasuriya, Mitchell H. Keylor, Ling Tong, Gregori J. Morriello, John J. Acton, Barbara Pio, Weiguo Liu, Jack D. Scott, Michael J. Ardolino, Theodore A. Martinot, Matthew L. Maddess, Xin Yan, Hakan Gunaydin, Rachel L. Palte, Spencer E. McMinn, Lisa Nogle, Hongshi Yu, Ellen C. Minnihan, Charles A. Lesburg, Ping Liu, Jing Su, Laxminarayan G. Hegde, Lily Y. Moy, Janice D. Woodhouse, Robert Faltus, Tina Xiong, Paul Ciaccio, Jennifer A. Piesvaux, Karin M. Otte, Matthew E. Kennedy, David Jonathan Bennett, Erin F. DiMauro, Matthew J. Fell, Santhosh Neelamkavil, Harold B. Wood, Peter H. Fuller, J. Michael Ellis
Publikováno v:
Journal of Medicinal Chemistry. 65:16801-16817
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::365ba0e1a6a6d085b4344b637344b726
https://doi.org/10.1021/acs.jmedchem.2c01605
https://doi.org/10.1021/acs.jmedchem.2c01605
Autor:
Ricky W. Johnstone, Saverio Minucci, J. Paul Secrist, Victoria M. Richon, Joey L. Methot, Thomas A. Miller, Nicole D. Ozerova, Astrid M. Kral, Susanna Chiocca, Claudia Miccolo, Ross A. Dickins, Ailsa J. Christiansen, Jessica E. Bolden, Carleen Cullinane, Kellie-Marie Banks, Christopher J.P. Clarke, Leonie A. Cluse, Michael Bots, Geoffrey M. Matthews, Andrea Newbold
PDF file - 1496K, Supplementary Methods; Supplementary Figure 1: Production and characterisation of tumor cells dependent on Bcr-Abl for survival; Supplementary Figure 2: HDACi with different isoform specificities induce apoptosis of Bcr-Abl(p210) ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51845ee47377f86143df810793c178b8
https://doi.org/10.1158/1535-7163.22498807.v1
https://doi.org/10.1158/1535-7163.22498807.v1
Autor:
Ricky W. Johnstone, Saverio Minucci, J. Paul Secrist, Victoria M. Richon, Joey L. Methot, Thomas A. Miller, Nicole D. Ozerova, Astrid M. Kral, Susanna Chiocca, Claudia Miccolo, Ross A. Dickins, Ailsa J. Christiansen, Jessica E. Bolden, Carleen Cullinane, Kellie-Marie Banks, Christopher J.P. Clarke, Leonie A. Cluse, Michael Bots, Geoffrey M. Matthews, Andrea Newbold
Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::367cd916bfc9f81672a5130168011dac
https://doi.org/10.1158/1535-7163.c.6535972.v1
https://doi.org/10.1158/1535-7163.c.6535972.v1
Autor:
Joey L. Methot, David A Candito, Sheila Ranganath, Zangwei Xu, Xavier Fradera, Abdelghani Achab, Erin F. DiMauro, Haiyan Xu, Samuel M. Levi, Brandon A. Vara, Brian M. Lacey, Mark Bittinger, Jennifer Piesvaux, Dustin M Smith, Alexander Pasternak, Jongwon Lim, David Jonathan Bennett, J. Richard Miller, Charles A. Lesburg, Shuhei Kawamura
Publikováno v:
ACS Med Chem Lett
[Image: see text] Hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase, is a negative immune regulator of T cell receptor (TCR) and B cell signaling that is primarily expressed in hematopoietic cells. Accordingly, it has been reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3974d15fa6854f44fa7ca9ad4baa4e1b
https://doi.org/10.1021/acsmedchemlett.1c00096
https://doi.org/10.1021/acsmedchemlett.1c00096
Autor:
Sam Kattar, Jason D. Katz, Peter Goldenblatt, Kenneth E. Wilson, Augustin, Matthew Christopher, Abdelghani Achab, Charles A. Lesburg, H. Zhou, Shrenik K. Shah, Xavier Fradera, Yudith Garcia, Joey L. Methot, Altman, McGowan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 29:2575-2580
PI3Kδ mediates key immune cell signaling pathways and is a target of interest for multiple indications in immunology and oncology. Here we report a structure-based scaffold-hopping strategy for the design of chemically diverse PI3Kδ inhibitors. Usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b939d5f9d279a3d02ee126d137ba8e4
https://doi.org/10.1016/j.bmcl.2019.08.004
https://doi.org/10.1016/j.bmcl.2019.08.004
Autor:
Joey L. Methot, Hua Zhou, Sam D. Kattar, Meredeth A. McGowan, Kevin Wilson, Yudith Garcia, Yongi Deng, Michael Altman, Xavier Fradera, Charles Lesburg, Thierry Fischmann, Chaomin Li, Steve Alves, Sanjiv Shah, Rafael Fernandez, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vince Tong, Robbie L. McLeod, Hongshi Yu, Alan Bass, Ray Kemper, Nicholas T. Gatto, Lisa LaFranco-Scheuch, Benjamin Wesley Trotter, Timothy Guzi, Jason D. Katz
Publikováno v:
Journal of Medicinal Chemistry. 62:4370-4382
PI3Kδ catalytic activity is required for immune cell activation, and has been implicated in inflammatory diseases as well as hematological malignancies in which the AKT pathway is overactive. A purine PI3Kδ inhibitor bearing a benzimidazolone-piper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22455e06a228a36e7b0e36ea97794591
https://doi.org/10.1021/acs.jmedchem.8b01818
https://doi.org/10.1021/acs.jmedchem.8b01818
Autor:
Jason D. Katz, François G. Gervais, Lauren Dorosh, Milenko Cicmil, Khamir Mehta, Joey L. Methot, Janice D Woodhouse, Hongshi Yu, Hani Houshyar, Prasanthi Geda, Gretchen A. Baltus, Malgorzata A Gil, Antonio Cabal, Sanjiv J. Shah, Robbie L. McLeod, Dapeng Chen, Alan S. Bass, Stephen E. Alves, Michael Caniga
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 369:223-233
We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)δ inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ae30672ed16800c8692f183b1d4851d
https://doi.org/10.1124/jpet.118.252551
https://doi.org/10.1124/jpet.118.252551
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
Autor:
Blair T. Lapointe, Jack D. Scott, Xin Cindy Yan, Haiqun Tang, Janice D Woodhouse, Kaleen Konrad Childers, Robert Faltus, Erin F. DiMauro, Solomon Kattar, Charles S. Yeung, Ravi Kurukulasuriya, Vladimir Simov, Hakan Gunaydin, Anmol Gulati, Joey L. Methot, Rachel L. Palte, Ellen C. Minnihan, Greg Morriello, J. Michael Ellis, Harold B. Wood, Santhosh Neelamkavil, Karin M. Otte, Michael J. Ardolino, Barbara Pio, Ping Liu, Laxminarayan G Hegde, Matthew J. Fell, Vanessa L. Rada, Peter Fuller, Paul J Ciaccio
Publikováno v:
RSC Med Chem
The discovery of potent, kinome selective, brain penetrant LRRK2 inhibitors is the focus of extensive research seeking new, disease-modifying treatments for Parkinson's disease (PD). Herein, we describe the discovery and evolution of a picolinamide-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8d45ea7dd7adda70471298a4476afa
https://europepmc.org/articles/PMC8292993/
https://europepmc.org/articles/PMC8292993/
Autor:
Benjamin Wesley Trotter, Xavier Fradera, Stephen E. Alves, Meredeth A. McGowan, Peter Goldenblatt, Jason D. Katz, Yudith Garcia, Lynsey Shaffer, Michael D. Altman, Matthew Christopher, Kathryn Lipford, Charles A. Lesburg, Hyun-Hee Lee, Chaomin Li, Craig P. Chappell, Vincent Tong, Elaine M. Pinheiro, Armetta D. Hill, Ruban Mangado, Renu Jain, Robbie L. McLeod, Sanjiv J. Shah, Hongshi Yu, Abdelghani Achab, Dapeng Chen, Joey L. Methot, Sybill M G Williams, Hua Zhou, Neville J. Anthony
Publikováno v:
Journal of medicinal chemistry. 64(8)
The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a62dfaa61d20ec22ebc7d156d70d73
https://pubmed.ncbi.nlm.nih.gov/33797901
https://pubmed.ncbi.nlm.nih.gov/33797901